Editions

Biotech & Longevity

A phase 3 drug just sold for $500,000 — the same week its old owner spent billions elsewhere →

A shelved antibiotic changed hands for less than the price of a flat. Across the week, J&J, Mission and Agenus all cut programs that other companies are queuing up to buy — while a 10-year prostate study showed a gentler treatment works and still barely reaches anyone.

Mind & Body

How your body knows which way is up — three senses cross-check each other, and the trouble starts when they disagree →

Balance isn't one sense. It's three independent reporters — the inner ear, the eyes, and the body's own joints — answering the same question and being compared. When their answers match, you feel nothing. When they don't, you feel sick.

Information Technology

AI advice made people three times less accurate — and twice as sure →

A new study found that access to an AI assistant collapsed people's willingness to say "I don't know" from 44% to 3%, while confidence more than doubled. On the same day, ecologists warned that AI-smoothed photos are seeding false bird sightings into the databases science relies on.

World News

Russia's largest missile salvo hits Kyiv as Europe's sanctions bloc frays →

Forty-one ballistic missiles and 125 drones struck the Ukrainian capital overnight — the biggest such attack of the war — while EU support for a new sanctions package crumbles. Meanwhile the US strikes Iran for a ninth straight night, Delhi braces for a banned protest march, and Netanyahu's party hands him the power to cancel its own primary.

Finance News

Oil passes $90 even as the Gulf ships more of it — and the rate debate turns →

Brent broke $90 on a ninth night of US strikes on Iran, capping a 15.9% week. The odd part: Gulf exports just hit their highest level since the war began. Traders are pricing the strait, not the barrels.

Food & Farming

A study says junk food may drive a third of heart disease — as regulators fight over what 'junk' even means →

New research links ultra-processed food to a large share of heart-disease deaths, just as the FDA and USDA struggle to define the category at all. The problem may be that our whole way of judging food looks at the wrong thing.

Gaming

Saudi Arabia's $55 billion buyout of EA clears its last big hurdle in Europe →

The largest leveraged buyout in history is nearly done — and the way it's paid for tells you more about EA's future than who now owns it.

Sports

MLB banned AI from the dugout — because the line between preparing and cheating had started to blur →

Baseball quietly outlawed teams from using artificial intelligence to help make live in-game calls. No one was punished. The league acted because a tool had made an old, unwritten line stop meaning what it used to.

Cybersecurity

A £11m con dressed as protection — and why the same trick runs your inbox →

A fraudster took 115 elderly people's homes by promising to keep them safe. Plus: a Colombian energy giant is extorted after a breach, and a week of stories about who is quietly watching you.

Biotech & Longevity

Merck's cholesterol pill clears the FDA — the first you can swallow, not inject →

A drug class proven for a decade finally comes as a once-a-day tablet. Plus: a gentler prostate treatment matches surgery, an oral psoriasis pill, and a vaccine aimed at stopping pancreatic cancer before it starts.

Climate & Energy

A new British PM is set to reopen the North Sea — and split his own party over it →

Andy Burnham is expected to approve new oil and gas drilling on his first day in Downing Street, reviving fields his own party once called "climate vandalism" and reopening the fight over whether homegrown fossil fuels actually lower anyone's bills.

Space

NASA ends its far-side moon-lander deal as delays push the landing toward 2031 →

NASA and Draper mutually cancelled a $73 million contract to land science instruments on the moon's far side, after redesign after redesign pushed the target from 2025 to 2031 — and the agency is already spreading the same science across other landers.

Personal Money

Opportunity cost — why the real price of anything is what you gave up to get it →

Every choice has two prices — the one printed on the receipt, and the value of the best thing that same money or time could have done instead. Here's how that hidden second price works, and why it quietly decides whether money grows or leaks.

Information Technology

Washington takes the keys to America's best AI — as China gives its own away →

The White House now approves who can access Anthropic and OpenAI's frontier models, even as it calls the arrangement "voluntary." The same week, China's Moonshot open-sourced a frontier-class model and Alibaba open-sourced the software to run AI off Nvidia's chips.

Mind & Body

How your blood clots — a chain reaction built to be stopped as fast as it starts →

Sealing a cut is not one event but four systems in tension: a plug, a self-amplifying chemical chain, a set of brakes that keep it local, and a crew that dissolves it. The brakes are the part that keeps the power from killing you.

World News

Venezuela's earthquake toll passes 5,000 as its own rescue is found to have stalled →

The death count from June's twin quakes crosses 5,000 and the IMF releases $346m — as a new investigation finds Venezuela's first days of rescue were crippled by delayed orders and tangled chains of command. Elsewhere, the US–Iran war grinds into a second week, Ukraine strikes deep inside Russia while protests swell at home, and Cuba's grid fails for a third time in ten days.

Finance News

Two governments go shopping: Italy's state moves to own the phone network, Britain seizes its last steelworks →

In one weekend, Italy's state-owned post office won board backing for a $14.9bn takeover of Telecom Italia, Britain finished nationalising British Steel, and China warned of retaliation. Strategic industry is being pulled back in-house — for reasons that have little to do with profit.

Food & Farming

One field, five states, many logos: a parasite in Taco Bell's lettuce reveals how few hands your food passes through →

A cyclospora outbreak traced to a single lettuce supplier sickened people across five states — and exposed how many separate-looking brands quietly share the same processor. Plus the stalled fight to even define "ultra-processed," and a call to investigate fertilizer pricing.

Personal Money

Net worth — the one number that counts what you keep, not what you make →

Your salary tells you how fast money flows in. Net worth tells you how much has stayed. They're different numbers, and the second is the one that measures whether you're actually getting ahead.

Climate & Energy

The EU moves to slow the climate rules it built to bind itself →

Brussels unveiled a plan to loosen its flagship carbon market and delay methane fines under US pressure — the same week Washington eased protections for endangered species. Behind both: a surge in electricity demand and near-term economic pressure that make long-term climate rules feel expensive now.

Cybersecurity

23andMe settles its DNA breach for $18m — but six million people can't change the data that leaked →

A record settlement over stolen genetic data, a city forcing "nudify" apps off the app stores, and clothes designed to blind facial recognition — a week whose real thread is the data you can never take back. Plus the ordinary, fixable flaws that still need patching now.

Finance News

Short sellers pocket $5 billion as SpaceX slides — a rare week when betting down paid →

SpaceX shares fell below their IPO price and short sellers profited about $5 billion, while money edged toward bonds and the Gulf kept a floor under oil.

Gaming

Xbox cut about 3,200 jobs — and this time the layoffs didn't stay quiet →

Microsoft's latest games-division cuts hit id Software, Bethesda and ZeniMax Online — but workers rallied in five cities and players flooded Xbox's own feedback site. Meanwhile EA's $55bn sale to a Saudi fund nears EU approval as it pushes into in-game ads, and AI tools are cloning indie games before they ship.

Biotech & Longevity

You can now bet on whether a drug will pass its trial — and that quietly changes the trial →

A prediction market opened contracts on clinical-trial results and FDA decisions, promising to surface truth the sponsors keep hidden. The same payoff hands a motive to anyone who can move or leak the result. Plus the first cholesterol pill of its kind, and a vaccine aimed at pancreatic cancer before it starts.

Space

India's first private rocket reaches for orbit — and cracks open a state monopoly →

A startup in Hyderabad launched India's first privately built orbital rocket today, joining a fast-growing commercial space push — while NASA quietly killed a delayed Moon lander and a record wave of money poured into orbit.

World News

A handful of chip stocks drag the whole market down →

A selloff in a few AI and chip giants pulled global markets into their worst week since spring, while US strikes on Iran entered a seventh night and Israel struck a Gaza funeral.

Mind & Body

How your body decides to breathe — it watches the waste, not the fuel →

The urge to breathe isn't set off by low oxygen. It's set off by carbon dioxide piling up — a faster, more reliable warning that usually tracks the danger. The trouble starts on the rare day the two come apart.

Information Technology

Amazon's cloud billed some customers up to $1.5 trillion — for a coffee's worth of service →

A billing bug at Amazon Web Services sent customers around the world invoices as high as $1.5 trillion before the company caught it. A Telstra outage, a new Chinese AI model, a rough week for chip stocks, and a run of ransomware round out the day.

Sports

The World Cup's video referee was built to end bad calls — instead it started a fight over who the rules are for →

FIFA changed refereeing rules mid-tournament, UEFA refused to copy them, and one country banned video review outright. Plus: the NFL suspends its own executive for betting while Britain moves against gambling sponsors, and Netflix airs its first Home Run Derby.

Cybersecurity

Companies are handing AI agents the keys to act on their own — and security wasn't built for helpers that can't be predicted →

Enterprises are granting AI agents broad, standing access to their systems, creating what one analysis calls "invisible privilege." Researchers showed a frontier model, given a single goal and enough autonomy, could run a full attack chain in a lab. The old rules assumed the thing holding your keys was a predictable human. It isn't anymore.

Food & Farming

A common pesticide is quietly harming the bees that pollinate a third of our food — while its makers keep winning in court →

New research finds a widely used pesticide damages bumblebee reproduction at low doses, even as pesticide firms stack legal wins over health and environmental groups. Out West, drought forces the same hard question — when something runs short, who loses first?

Sports

Manchester United paid Chelsea £48m for Andrey Santos — and selling him was near-pure profit →

Chelsea keeps turning cheaply-bought youngsters into accounting gold, because the way a transfer sits on the books decides which player it makes sense to sell.

Gaming

Sony's plan to kill the game disc is a door that only opens one way →

Sony will stop making PlayStation discs in January 2028, and this week Mexican lawmakers moved to sue over it — a fight about whether the shift to all-digital can ever be undone. Plus EA eyes in-game ads, and AI floods the indie scene with clones.

Biotech & Longevity

An Ebola trial was built in six weeks — while the outbreak's frontline collapses for lack of pay →

A record-fast treatment trial and a new vaccine show what years of pooled preparation can do. Unpaid, attacked burial teams show how quickly coordination breaks at the bottom.

Climate & Energy

A top science panel says extreme weather now carries fingerprints →

The U.S. National Academies formally backs the science of tying specific storms and heatwaves to climate change — as Washington and Europe both look for ways to slow the energy transition down.

Personal Money

How insurance actually works — why thousands of strangers quietly cover your worst day →

You pay a small sum each year hoping never to use it. That's not a bad deal — it's the whole point. Here's the machinery of risk pooling, why the maths works, and where it quietly breaks.